Clinical trial
A Phase I, Open Interaction Study Between Oral Doses of GLPG1837 and Single Doses of Midazolam in Healthy Male Subjects
NCT02562950 is registered in ClinicalTrials.gov with Lakefront Biotherapeutics NV as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Open Interaction Study Between Oral Doses of GLPG1837 and Single Doses of Midazolam in Healthy Male Subjects
- Lead sponsor
- Lakefront Biotherapeutics NV
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 30, 2015
- Completion date
- October 31, 2015
- Enrollment
- 24 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy